Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP20166312A	2023-02-28	SANDOZ AG	Granted and Under Opposition
EP18209003A	2020-12-30	Sandoz AG	Granted and Under Opposition
EP16704744A	2019-09-05	Breuer, Markus	Revoked
EP16704744A	2019-09-05	European Oppositions Limited	Revoked
EP16704744A	2019-09-04	ALLERGAN, INC.	Revoked

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US10596107	January, 2019	Decision	Mohannad Shawer et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11534395	BAUSCH AND LOMB INC	Ophthalmic suspension composition	Jan, 2036 (12 years from now)
US10596107	BAUSCH AND LOMB INC	Ophthalmic suspension composition	Dec, 2036 (13 years from now)

Lotemax Sm is owned by Bausch And Lomb Inc.

Lotemax Sm contains Loteprednol Etabonate.

Lotemax Sm has a total of 2 drug patents out of which 0 drug patents have expired.

Lotemax Sm was authorised for market use on 22 February, 2019.

Lotemax Sm is available in gel;ophthalmic dosage forms.

Lotemax Sm can be used as treatment of post-operative inflammation and pain following ocular surgery.

The generics of Lotemax Sm are possible to be released after 23 December, 2036.

Drug Exclusivity	Drug Exclusivity Expiration
New Strength (NS)	Feb 22, 2022

Market Authorisation Date: 22 February, 2019

Treatment: Treatment of post-operative inflammation and pain following ocular surgery

Dosage: GEL;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0038	14 Nov, 2022	1		23 Dec, 2036

Strength	Dosage	Availability
0.38%	GEL;OPHTHALMIC	Prescription

LOTEMAX SM family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic